目的:为研究 HER2阳性乳腺癌细胞获得拉帕替尼耐药性的机制,建立稳定具有拉帕替尼耐药性的细胞株。方法:采用2μmol∕ L 的拉帕替尼处理 HER2阳性乳腺癌细胞 BT -474,维持12个月,使细胞获得稳定耐药性。然后分别利用 MTT、平板克隆和软琼脂克隆形成能力分析等方法,评价所建立耐药细胞的耐药能力。结果:所建立的耐药细胞在细胞增殖能力、平板克隆形成能力和软琼脂克隆形成能力等方面均具有耐药性。结论:建立的拉帕替尼耐药性细胞 BT -474具有稳定的耐药性,为后续机制研究奠定基础。
Objective:To establish the HER2 positive breast cancer cell lines with stable resistance to Lapatinib. Methods:Treat the HER2 positive breast cancer cell BT - 474 with 2μmol∕ L Lapatinib for 12 months. Then analyze the resistance ability with MTT,colony formation and soft agar assay. Results:BT - 474 resistant cell showed dramatic resistance to Lapatinib whenever analyzing with MTT,colony formation and soft agar assay. Conclusion:The estab-lished resistant cell BT - 474LapR demonstrated stable resistance to Lapatinib compared to the parental cell.